Create account

Coverage dated October 19, 2026 to October 20, 2026

Some GLP-1 injections recalled due to 'lack of assurance of sterility'

Headline from Los Angeles Times

Apothecary Pharma, a compounding pharmacy, voluntarily recalled 22 vials of Tirzepatide injections due to a "lack of assurance of sterility," according to the official announcement.

Los Angeles Times's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.

Read the reports

Reports & sources

4 articles, oldest first.

  1. Money Talks News

    GLP-1 Injections Recalled Nationwide. See Affected Products (opens Money Talks News)

    Published

    Money Talks News's feed description

    Twenty-two vials of compounded tirzepatide are affected, and the pharmacy had an FDA warning letter on sterility problems before the recall.

  2. New York Post

    GLP-1 injections recalled nationwide — what to know about the affected products (opens New York Post)

    Published

    New York Post's feed description

    The US-based pharmacy that issued the initial recall had previously received a warning.

  3. FOX Business

    GLP-1 injections recalled nationwide over sterility concerns (opens FOX Business)

    Published

    FOX Business's feed description

    The FDA classified Apothecary Pharma's nationwide recall of 23 injectable drug vials as Class II. The company previously received a warning over sterile drug production.

  4. Los Angeles Times

    Some GLP-1 injections recalled due to 'lack of assurance of sterility' (opens Los Angeles Times)

    Published

    Los Angeles Times's feed description

    Apothecary Pharma, a compounding pharmacy, voluntarily recalled 22 vials of Tirzepatide injections due to a "lack of assurance of sterility," according to the official announcement.

Some GLP-1 injections recalled due to 'lack of assurance of sterility' | Since Then